Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London's Katie Pilbeam to discuss the progress of their pipeline, particularly their clinical pipeline.
Anson recaps on its lead product RXC004 which is in a Phase I clinical trial and is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. With Phase II expected to take place later this year.
Anson also updates investors on their second programme, RXC007, a drug which has potential for development in multiple fibrotic conditions.
She details the recent investment by its majority shareholder Redmile which has increased its stake to 91.76% from 58.25%.
They have also established partnerships with large pharma companies such as AstraZeneca and Jazz Pharmaceuticals.